Roxadustat
Roxadustat (FG-4592), hypoxia-inducible factor prolyl hydroxylase inhibitor
N/A Amino Acids · MW: 352.35 Da
Amino Acids
N/A
Molecular Weight
352.35 Da
Half-life
~12-16 h
Research Score
4.1
Studies
180
Storage
Store lyophilized at -20°C, reconstituted at 2-8°C
What is Roxadustat?
Roxadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor that increases endogenous erythropoietin and improves iron utilization. Its endurance relevance comes from raising hemoglobin and oxygen transport, not from direct muscle stimulation.
Key Benefits & Mechanisms
induces endogenous EPO
improves iron handling
raises hemoglobin
may improve exercise tolerance
Research Summary
Large clinical studies support roxadustat for anemia, especially in chronic kidney disease populations. Direct VO2 max enhancement data in healthy athletes are limited, so its performance effects remain mostly inferential.
Related Peptides
FS315
Follistatin-315 (FS315)
The circulating major isoform of follistatin that binds activins and can modulate myostatin signaling. It is widely used in research because it is the more common endogenous secreted form in human plasma.
Muscle & PerformanceACE-031
ACE-031 (soluble activin receptor type IIB-Fc)
A recombinant decoy receptor fusion protein that traps myostatin and related ligands such as activins. It was developed to promote skeletal muscle growth and counteract wasting.
Muscle & PerformanceBYM338
Bimagrumab (BYM338)
A human monoclonal antibody against activin type II receptors that blocks myostatin/activin signaling at the receptor level. It has been studied for sarcopenia, obesity with muscle preservation, and several wasting conditions.
Muscle & PerformanceREGN1033
Trevogrumab (REGN1033)
A human monoclonal antibody that neutralizes myostatin, the key negative regulator of skeletal muscle growth. It has been evaluated for muscle loss states and as a body-composition modulator in combination regimens.
Muscle & Performance